Evidence map›Paper›PMID 28197367›Full record

ArticleOncoimmunology

Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Sareetha Kailayangiri, Bianca Altvater, Christian Spurny, Silke Jamitzky, Sonja Schelhaas, Andreas H Jacobs, Constanze Wiek, Katharina Roellecke, Helmut Hanenberg, Wolfgang Hartmann and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Breaking Immunosuppression to Enhance Cancer Stem Cell-Targeted Immunotherapy.International journal of biological sciences · 2025
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Frontiers in oncology · 2024
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Soluble NKG2D ligands impair CD8Oncology letters · 2023
    Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Sareetha KailayangiriDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany.
Bianca AltvaterDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany.
Christian SpurnyDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany.
Silke JamitzkyDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany.
Sonja SchelhaasEuropean Institute for Molecular Imaging (EIMI), University of Muenster , Muenster, Germany.
Andreas H JacobsEuropean Institute for Molecular Imaging (EIMI), University of Muenster, Muenster, Germany; Cells-in-Motion Cluster of Excellence (EXC 1003 - CiM), University of Muenster, Muenster, Germany.
Constanze WiekDepartment of Otorhinolaryngology, Head and Neck Surgery, Children's Hospital, Heinrich Heine University , Duesseldorf, Germany.
Katharina RoelleckeDepartment of Otorhinolaryngology, Head and Neck Surgery, Children's Hospital, Heinrich Heine University , Duesseldorf, Germany.
Helmut HanenbergDepartment of Otorhinolaryngology, Head and Neck Surgery, Children's Hospital, Heinrich Heine University, Duesseldorf, Germany; Department of Pediatrics III, University Children's Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Wolfgang HartmannGerhard-Domagk Institute for Pathology, University of Muenster , Muenster, Germany.
Heinz WiendlCells-in-Motion Cluster of Excellence (EXC 1003 - CiM), University of Muenster, Muenster, Germany; Department of Neurology, University Hospital Muenster, Muenster, Germany.
Susann PankratzDepartment of Neurology, University Hospital Muenster , Muenster, Germany.
Jutta MeltzerDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany.
Nicole FarwickDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany.
Lea GreuneDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany.
Maike FlueggeDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster , Muenster, Germany.
Claudia RossigDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany; Cells-in-Motion Cluster of Excellence (EXC 1003 - CiM), University of Muenster, Muenster, Germany.
University Hospital Münster · DEHeinrich Heine University Düsseldorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activated and

Indexed as

Chimeric antigen receptorsEwing sarcomaHLA-Ginhibitory immune checkpointsNK cells

Identifiers

PMID28197367
PMCPMC5283645
OpenAlexW2546024518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.